🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million new cases per year. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the American regulatory agency in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the current standard treatment, which uses an injection and a pill. The trial included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in many regions with limited resources.

Medical professionals on the front lines have voiced hope. Access to a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is considered crucial to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.